Anti-TNFα therapy for chronic inflammatory disease in kidney transplant recipients

Medicine (United States) - Tập 95 Số 41 - Trang e5108 - 2016
Cyril Garrouste1, Dany Anglicheau2,3,4,5,6,7, Nassim Kamar8,9, Claire Bachelier10, Joseph Rivalan11, Bruno Pereira12, Sophie Caillard13,14, Julien Aniort15, Philippe Gatault16, Martin Soubrier17,15, Johnny Sayegh18, Charlotte Colosio19, Anthony Buisson20, Éric Thervet21,22,23, Nicolas Bouvier24, Anne Elisabeth Heng11
1CHU Clermont-Ferrand, France
2Centaure Foundation [Hôpital Necker - APHP] (France)
3INEM - UM 111 (UMR 8253 / U1151) - Institut Necker Enfants-Malades (Bâtiment Leriche 14 rue Maria Helena Vieira Da Silva 75014 Paris - France)
4Labex Transplantex [Hôpital Necker - APHP] (France)
5Service de néphrologie et transplantation rénale [Hôpital Necker Enfants Malades - APHP] (France)
6UPD5 - Université Paris Descartes - Paris 5 (12, rue de l'École de Médecine - 75270 Paris cedex 06 - France)
7USPC - Université Sorbonne Paris Cité (Université Sorbonne Paris Cité | 100-104, avenue de France | 75013 Paris - France)
8I2MR - Institut de médecine moléculaire de Rangueil (Institut Louis Bugnard 1, avenue Jean Poulhes BP 84225 31432 TOULOUSE CEDEX 4 - France)
9PHARMA-DEV - Pharmacochimie et Biologie pour le Développement (IRD UMR 152 Université Paul Sabatier 35 Chemin des Maraîchers 31400 Toulouse - France)
10CHU Clermont-Ferrand, Department of Nephrology, Clermont-Ferrand
11Service de néphrologie [Rennes] (CHU de Rennes - 35033 Rennes - France)
12Biostatistiques (France)
13HUS - Les Hôpitaux Universitaires de Strasbourg (1 place de l'hôpital BP 426 67091 Strasbourg cedex - France)
14IRM - Immuno-Rhumatologie Moléculaire (1 Place de l'Hôpital 67000 Strasbourg - France)
15UNH - Unité de Nutrition Humaine (Site INRAE Theix : 63122 Saint-Gènes-Champanelle // Site Clermont : UFR de Médecine et de Pharmacie, TSA 50400, 28 Place Henri Dunant, 63001 Clermont-Ferrand - France)
16Service de néphrologie et immunologie clinique [CHRU Tours] (2 Boulevard Tonnellé, 37000 Tours - France)
17Service Rhumatologie [CHU Clermont-Ferrand] (CHU Clermont-Ferrand - Site Gabriel-Montpied, 58 Rue Montalembert, 63000 Clermont-Ferrand - France)
18Department of Kidney Transplantation CHU Angers (CHU ANGERS - France)
19CHU Reims - Hôpital universitaire Robert Debré [Reims] (rue du General Koenig 51090 Reims Cedex - France)
20M2iSH - Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (UFR de Médecine et de Pharmacie, 28 Place Henri Dunant, BP 38, 63001 Clermont-Ferrand Cedex - France)
21CHU Tenon [AP-HP] (4 Rue de la Chine, 75020 Paris - France)
22PARCC - UMR-S U970 - Paris-Centre de Recherche Cardiovasculaire (56 rue Leblanc 75015 PARIS FRANCE - France)
23Physiologie - Explorations fonctionnelles [AP-HP HEGP, Paris] (20 Rue Leblanc, 75015 Paris. - France)
24CHU Caen (Avenue de la Côte de Nacre 14000 Caen - France)

Tóm tắt

Từ khóa


Tài liệu tham khảo

Al-Lamki, 2015, TNF receptors: signaling pathways and contribution to renal dysfunction, Kidney Int, 87, 281, 10.1038/ki.2014.285

Palladino, 2003, Anti-TNF-alpha therapies: the next generation, Nat Rev Drug Discov, 2, 736, 10.1038/nrd1175

Fishman, 2007, Infection in solid-organ transplant recipients, N Engl J Med, 357, 2601, 10.1056/NEJMra064928

Nanau, 2014, Safety of anti-tumor necrosis factor therapies in arthritis patients, J Pharm Pharm Sci, 17, 324, 10.18433/J3WP4F

AlBugami, 2014, Malignancies: pre and post transplantation strategies, Transplant Rev (Orlando, 28, 76, 10.1016/j.trre.2013.12.002

Pena-Sagredo, 2008, Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience, Clin Exp Rheumatol, 26, 854

Lanternier, 2013, Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study, Chest, 144, 990, 10.1378/chest.12-2820

Winthrop, 2013, Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster, JAMA, 309, 887, 10.1001/jama.2013.1099

Winthrop, 2013, Mycobacterial diseases and antitumour necrosis factor therapy in USA, Ann Rheum Dis, 72, 37, 10.1136/annrheumdis-2011-200690

Salmon-Ceron, 2011, Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry, Ann Rheum Dis, 70, 616, 10.1136/ard.2010.137422

Lebrec, 2015, Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk, Curr Med Res Opin, 31, 557, 10.1185/03007995.2015.1011778

Sandhu, 2012, The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series, Aliment Pharmacol Ther, 36, 159, 10.1111/j.1365-2036.2012.05141.x

El-Nachef, 2010, Anti-tumor necrosis factor therapy for inflammatory bowel disease in the setting of immunosuppression for solid organ transplantation, Am J Gastroenterol, 105, 1210, 10.1038/ajg.2010.33

Schnitzler, 2015, Solid organ transplantation in patients with inflammatory bowel diseases (IBD): analysis of transplantation outcome and IBD activity in a large single center cohort, PLoS One, 10, e0135807, 10.1371/journal.pone.0135807

Temme, 2010, Infliximab as therapeutic option in steroid-refractory ulcerative colitis after kidney transplantation: case report, Transplant Proc, 42, 3880, 10.1016/j.transproceed.2010.08.044

Hoover, 2007, Etanercept therapy for severe plaque psoriasis in a patient who underwent a liver transplant, Cutis, 80, 211

Mohabbat, 2012, Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients, Aliment Pharmacol Ther, 36, 569, 10.1111/j.1365-2036.2012.05217.x

Leroy, 2009, Successful anti-TNFalpha treatment in a child with posttransplant recurrent focal segmental glomerulosclerosis, Am J Transplant, 9, 858, 10.1111/j.1600-6143.2009.02550.x

Solez, 2008, Banff 07 classification of renal allograft pathology: updates and future directions, Am J Transplant, 8, 753, 10.1111/j.1600-6143.2008.02159.x

Lal, 2007, Infliximab for ulcerative colitis following liver transplantation, Eur J Gastroenterol Hepatol, 19, 277, 10.1097/MEG.0b013e3280116ccc

Page, 2008, Tumor necrosis factor-alpha inhibitor-induced lupus-like syndrome presenting as fever of unknown origin in a liver transplant recipient: case report and concise review of the literature, Transplant Proc, 40, 1768, 10.1016/j.transproceed.2008.03.102

Indriolo, 2013, Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation, Aliment Pharmacol Ther, 37, 840, 10.1111/apt.12256

Brokalaki, 2012, Treatment of severe psoriasis with etanercept in a pancreas-kidney transplant recipient, Transplant Proc, 44, 2776, 10.1016/j.transproceed.2012.09.008

Collazo, 2008, Etanercept therapy for psoriasis in a patient with concomitant hepatitis C and liver transplant, P R Health Sci J, 27, 346

Madankumar, 2015, Use of etanercept for psoriasis in a liver transplant recipient, JAAD Case Rep, 1, S36, 10.1016/j.jdcr.2015.09.012

Metyas, 2007, The use of the tumour necrosis factor antagonist infliximab in heart transplant recipients: two case reports, Ann Rheum Dis, 66, 1544, 10.1136/ard.2007.070383

Arnott, 2003, Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety, Pharmacol Res, 47, 1, 10.1016/S1043-6618(02)00264-5

Schreiber, 2001, Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001–2003, Int J Colorectal Dis, 16, 1, 10.1007/s003840100285

Long, 2012, Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease, Gastroenterology, 143, 390.e1, 10.1053/j.gastro.2012.05.004

Beaugerie, 2009, Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study, Lancet, 374, 1617, 10.1016/S0140-6736(09)61302-7

Magro, 2014, Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III), J Crohns Colitis, 8, 31, 10.1016/j.crohns.2013.04.006

Soderlund, 2009, Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease, Gastroenterology, 136, 1561, 10.1053/j.gastro.2009.01.064

Castano-Milla, 2014, Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis, Aliment Pharmacol Ther, 39, 645, 10.1111/apt.12651

Baecklund, 2006, Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis, Arthritis Rheum, 54, 692, 10.1002/art.21675

Bongartz, 2006, Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials, JAMA, 295, 2275, 10.1001/jama.295.19.2275

Amari, 2011, Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis, Rheumatology (Oxford, 50, 1431, 10.1093/rheumatology/ker113

Williams, 2014, Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel disease, Aliment Pharmacol Ther, 39, 447, 10.1111/apt.12624

Peyrin-Biroulet, 2011, Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease, Gastroenterology, 141, 1621.e1, 10.1053/j.gastro.2011.06.050

Baars, 2011, The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study, Am J Gastroenterol, 106, 319, 10.1038/ajg.2010.428

Scott, 2016, Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer, JAMA Dermatol, 152, 164, 10.1001/jamadermatol.2015.3029

Raaschou, 2013, Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden, BMJ, 346, f1939, 10.1136/bmj.f1939

Penn, 1993, The effect of immunosuppression on pre-existing cancers, Transplantation, 55, 742, 10.1097/00007890-199304000-00011

Bernheim, 2015, Previous cancer/lymphoma and refractory inflammatory bowel disease, Dig Dis, 33, 44, 10.1159/000437064

Axelrad, 2016, Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents, Clin Gastroenterol Hepatol, 14, 58, 10.1016/j.cgh.2015.07.037

Imagawa, 1991, The role of tumor necrosis factor in allograft rejection. III. Evidence that anti-TNF antibody therapy prolongs allograft survival in rats with acute rejection, Transplantation, 51, 57, 10.1097/00007890-199101000-00008

Korsten, 2010, Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab, Am J Kidney Dis, 56, e17, 10.1053/j.ajkd.2010.08.019

Yoshioka, 2013, [Granulomatous interstitial nephritis in a patient with Behcet's disease treated with infliximab], Nihon Jinzo Gakkai Shi, 55, 1412

Williams, 2011, TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists, Int J Dermatol, 50, 619, 10.1111/j.1365-4632.2011.04871.x

Shakoor, 2002, Drug-induced systemic lupus erythematosus associated with etanercept therapy, Lancet, 359, 579, 10.1016/S0140-6736(02)07714-0

Williams, 2009, Anti-TNF-induced lupus, Rheumatology (Oxford, 48, 716, 10.1093/rheumatology/kep080

Stokes, 2005, Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis, Nephrol Dial Transplant, 20, 1400, 10.1093/ndt/gfh832

Lahiri, 2015, Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis, Best Pract Res Clin Rheumatol, 29, 290, 10.1016/j.berh.2015.05.009

Knoll, 2013, Kidney transplantation in the older adult, Am J Kidney Dis, 61, 790, 10.1053/j.ajkd.2012.08.049